MMP14 and sarcoma: We report the development of a dual-modal (PET/NIRF)imaging agentbased on a site-specifically glycoengineered anti-MT1-MMP (LEM2/15.8)immunoconjugate for pre-operative PET-based assessment and FGS ofMT1-MMP-overexpressing sarcomas.